Showing 4,541 - 4,560 results of 28,436 for search '(( 50 ((ns decrease) OR (a decrease)) ) OR ( 5 ((ng decrease) OR (nn decrease)) ))', query time: 0.81s Refine Results
  1. 4541
  2. 4542
  3. 4543
  4. 4544

    Pre-diabetes is associated with increased risk of heart failure among patients with atrial fibrillation by Jia-Yi Huang (12733928)

    Published 2022
    “…Compared to those who remained pre-diabetic, patients who progressed to diabetes were associated with an increased risk of HF (SHR=1.50, 95% CI: 1.13-1.97), whereas those who reversed to normoglycaemia were associated with decreased risk (SHR=0.61, 95% CI: 0.42-0.94). …”
  5. 4545
  6. 4546

    Discovery of the Diphenyl 6‑Oxo-1,6-dihydropyridazine-3-carboxylate/carboxamide Analogue J27 for the Treatment of Acute Lung Injury and Sepsis by Targeting JNK2 and Inhibiting the... by Jing Liao (193197)

    Published 2023
    “…The optimal compound <b>J27</b> decreased the release of TNF-α and IL-6 in mouse and human cells J774A.1 and THP-1 (IL-6 IC<sub>50</sub> = 0.22 μM) through the NF-κB/MAPK pathway. …”
  7. 4547

    Discovery of the Diphenyl 6‑Oxo-1,6-dihydropyridazine-3-carboxylate/carboxamide Analogue J27 for the Treatment of Acute Lung Injury and Sepsis by Targeting JNK2 and Inhibiting the... by Jing Liao (193197)

    Published 2023
    “…The optimal compound <b>J27</b> decreased the release of TNF-α and IL-6 in mouse and human cells J774A.1 and THP-1 (IL-6 IC<sub>50</sub> = 0.22 μM) through the NF-κB/MAPK pathway. …”
  8. 4548

    DataSheet_1_Decreasing the steroid rapidly may help to improve the clinical outcomes of patients with intestinal steroid-refractory acute graft-versus-host disease receiving basili... by Cong Cheng (2140318)

    Published 2024
    “…Hence, it was helpful to decrease steroid to the 50% of initial dose ≤ 5 days and to the low-dose steroid ≤ 12 days after basiliximab treatment for intestinal SR-aGVHD patients, which may also be the reasonable steroid decrease protocol for these patients.…”
  9. 4549
  10. 4550

    Developmental regulation of BLBP-positive radial glia and BrdU-positive proliferative cells in the <i>Xenopus</i> tectum. by Yi Tao (178829)

    Published 2015
    “…Right panel: a higher magnification image of the right tectum, Scale: 50 μm. …”
  11. 4551

    Analysis of AMPA-R mediated EPSCs (aEPSCs) at CA1 synapses in hippocampal slices from P10 mice ICV injected at P1, P3, and P5 with saline or GR1. by Nicole M. Lykens (3727072)

    Published 2017
    “…Representative traces of maximal aEPSCs are shown from saline and GR1-treated mice (scale bars: 50 ms; 200 pA). …”
  12. 4552
  13. 4553
  14. 4554

    Supplementary Material for: Mild to Moderate, but Not Minimal or Severe, Acute Histologic Chorioamnionitis or Intra-Amniotic Inflammation Is Associated with a Decrease in Respirato... by Park C.-W. (4153468)

    Published 2015
    “…Patients were divided into 4 groups according to the severity of acute-HCA (i.e. total grade: minimal, 1; mild, 2; moderate, 3-4; severe, 5-6) or IAI (i.e. amniotic fluid MMP-8: minimal, 23-100 ng/ml; mild, 100-400 ng/ml; moderate, 400-800 ng/ml; severe, ≥800 ng/ml). …”
  15. 4555
  16. 4556
  17. 4557
  18. 4558

    Short-term insulin intensive therapy decreases MCP-1 and NF-κB expression of peripheral blood monocyte and the serum MCP-1 concentration in newlydiagnosed type 2 diabetics by Yang Lin (162495)

    Published 2018
    “…Results After 2 weeks of the treatment, MCP-1 and NF-κB protein expression of peripheral blood monocyte and serum MCP-1 levels decreased significantly compared with those of pre-treatment, which were (0.50 ± 0.18)% vs (0.89 ± 0.26)% (12.22 ± 2.80)% vs (15.53 ± 2.49)% and (44.53 ± 3.97) pg/mL vs (49.53 ± 3.47) pg/mL, respectively (P < 0.01). …”
  19. 4559

    Short-term insulin intensive therapy decreases MCP-1 and NF-κB expression of peripheral blood monocyte and the serum MCP-1 concentration in newlydiagnosed type 2 diabetics by Yang Lin (162495)

    Published 2018
    “…Results After 2 weeks of the treatment, MCP-1 and NF-κB protein expression of peripheral blood monocyte and serum MCP-1 levels decreased significantly compared with those of pre-treatment, which were (0.50 ± 0.18)% vs (0.89 ± 0.26)% (12.22 ± 2.80)% vs (15.53 ± 2.49)% and (44.53 ± 3.97) pg/mL vs (49.53 ± 3.47) pg/mL, respectively (P < 0.01). …”
  20. 4560